Syphilis patients may be most affected by penicillin shortage

John Gregory | | Health Exec | Policy & Regulations

Pfizer’s “unanticipated manufacturing delay” involving the recommended treatment for syphilis will pose problems for the growing number of patients with the sexually transmitted infection.

For more on the CDC’s efforts to prioritize available penicillin for syphilis patients, click on the link below: 

Penicillin Shortage Could Be A Problem For People With Syphilis

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Veterans Affairs denies it discriminates based on politics, marital status
Dexcom recalls more than 2 million CGM receivers over safety issues—dozens of adverse events reported
Ivenix infusion kits recalled by FDA due to serious manufacturing defect
FDA recalls pediatric breathing kits after eight serious injuries
Judge rips Trump administration for terminating DEI-advancing NIH grants: ‘Have we no shame?’
FDA recalls Zyno infusion pumps, citing risk of death

Around the web

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

Cardiovascular Business
Smaller revenues, less growth: In US, tariffs may create headaches for $34.5B cardiovascular device market

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.